"what i mean is no mention that Majorelle CEO already knows"
Ah, so Value (sorry Timothy) failed to mention that Mehdi el-Glaoui "knew" that he would get lots of sales in France not only from men but from the use of Vitaros by women.
Well, on that point I would agree that there will be "off label" use of Vitaros by women. However, I would maintain that use by women will be incidental for at least the next couple of years and a very small fraction of the overall sales. If years passed by and there was no approval of Femprox, then I would expect that Vitaros use by women might increase substantially over incidental use.
News 
Market Data 
Discover 
AI
